Ab­b­Vie clos­es in on Bio­haven with new mi­graine pre­ven­tion OK for oral CGRP drug

You can now add an­oth­er hefty phar­ma play­er to the com­mer­cial bat­tle for mi­graine pre­ven­tion.

Ab­b­Vie has land­ed an ap­proval for Qulip­ta, the oral CGRP re­cep­tor an­tag­o­nist it ob­tained via the $63 bil­lion buy­out of Al­ler­gan and the third FDA-ap­proved drug in its mi­graine port­fo­lio.

While Ab­b­Vie’s oth­er CGRP drug, Ubrelvy, won an OK for acute treat­ment of mi­graine ahead of Bio­haven, the Yale biotech spin­out snared a leg up this May when it scored an ex­pand­ed la­bel for Nurtec to cov­er the pre­ven­ta­tive use.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER